Allopregnanolone as regenerative therapeutic for alzheimer's: phase 2 clinical trial

Active Project Grant Awarded Last action

Award ID
R01AG063826
Recipient
Awarding agency
Obligated
$57,636,951

Award facts

Assistance listing
93.866 Aging Research
Completion date 94% complete
Originally
Place of performance
Tucson, AZ 85721, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $6,580,973
Amendment $6,580,973
Amendment $6,580,973
Amendment $0
Amendment $7,279,977
Amendment $7,279,977
Amendment $7,552,351
Amendment $7,370,815
Amendment $0
Amendment $0
Original award $8,410,912
Show all 14

Subawards

Subrecipient Amount Awarded
University Of Southern California Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial $72,885
ADM Diagnostics, Inc. $769,363
Syneos Health LLC $13,900,892

Quick answers

Who received award R01AG063826?

R01AG063826 was awarded to University Of Arizona by National Institute on Aging (National Institutes of Health) on August 8, 2019.

How much is award R01AG063826 worth?

$57,636,951 has been obligated on R01AG063826.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award